Authors : Zufnoon Khan; Neelam Jain; Abeer Kulsoom

Volume/Issue : Volume 10 - 2025, Issue 1 - January

Google Scholar : https://tinyurl.com/h6hu6c85

Scribd : https://tinyurl.com/5xdc8rbj

DOI : https://doi.org/10.5281/zenodo.14869985

Abstract : Pharmacovigilance detects, evaluates, and prevents adverse drug reactions (ADRs), one of the primary avoidable causes of sickness and death. With the National Pharmacovigilance Program (NPP) and Pharmacovigilance Program of India (PvPI), pharmacovigilance has gained popularity in India to monitor medication safety and improve public health. Despite advances, ADR underreporting, healthcare professional ignorance, and infrastructural issues exist. India has used digital transformation, mobile applications, AI, and ML to improve ADR detection, real-time monitoring, and data analysis. Blockchain technology is being investigated for data integrity and reporting transparency. However, privacy problems, remote digital resource availability, and regulatory uncertainty restrict these ideas' potential. India plans to improve its pharmacovigilance by concentrating on genomic drug safety, worldwide cooperation, and telemedicine integration for real-time monitoring. These activities will enhance medication safety, minimize adverse drug reactions, and support global pharmacovigilance, making healthcare safer.

Keywords : Pharmacovigilance, Adverse Drug Reactions, Digital Transformation, AI, Machine Learning, Blockchain, India, Drug Safety.

References :

1. WHO Policy Perspectives on Medicines. Geneva: WHO; 2004. Geneva: World Health Organization. Looking at the Pharmacovigilance: ensuring the safe use of medicines.
2. Klepper MJ. The periodic safety update report as a pharmacovigilance tool. Drug Saf 2004;27:569 78.
3. Livio F, Renard D, Buclin T. Pharmacovigilance. Rev Med Suisse 2012;8:116-9.
4. Pharmacovigilance. Mann RD, Andrews EB, eds. John Wiley & Sons Ltd, Chichester, 2002.
5. Ankur Rohilla, Nishant Singh, Vipin Kumar, Amarjeet Dahiya, Review article of the Pharmacovigilance.
6. Biswas P, Biswas A. Setting standards for proactive pharmacovigilance in India: The way forward. Ind J Pharmacol 2007;39:124-8.
7. Skalli S, Soulaymani Bencheikh R. Safety monitoring of herb-drug interactions: a component of pharmacovigilance. Drug Saf 2012;35:785-91.
8. WHO, Pharmacovigilance: ensuring the safe use of medicines, Geneva: WHO 2004.
9. WHO, Safety of medicines in public health programmes: pharmacovigilance an essential tool,WHO,2006.
10. WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy 2000- 2003.
11. Olsson S. The role of the WHO Programme for International Drug Monitoring in coordinating worldwide drug safety efforts. Drug Saf 1998;19:1 10.
12. The importance of pharmacovigilance. Geneva: World Health Organization; 2002.
13. Joshi SR, Sapatnekar SM. Pharmacovigilance in India: how safe are the new drugs? How sure are we? J Assoc Physicians Ind 2008;56:933-4.
14. Olsson S. Pharmacovigilance training with focus on India. Ind J Pharmacol 2008;40: S28-S30.
15. Olsson S. Pharmacovigilance training with focus on India. Ind J Pharmacol 2008:40:S28-S30.
16. The importance of pharmacovigilance; safety monitoring of medical products, Geneva, WHO, 2002
17. Pharmacovigilance: A Worldwide Master Key for Drug Safety Monitoring. G.Jeetu and G.Anusha.
18. Pharmacovigilance Programme of India Duvvuru Ashok Kumar*, Languluri Reddenna, Shaik Ayub Basha.
19. Shakir SAW. PEM in the UK. In: Mann RD, Andrews EB, eds. Pharmacovigilance Chichester, John Wiley and Sons, 2002:333-344
20. Strom BL (ed.) Pharmacoepidemiology, 3rd ed. New York, NY, John Wiley and Sons, Ltd, 2002.
21. Skalli S, Soulaymani Bencheikh R. Safety monitoring of herb-drug interactions: acomponent of pharmacovigilance. Drug Saf 2012;35:785-91.
22. Shakir SAW. PEM in the UK. In: Mann RD, Andrews EB, eds. Pharmacovigilance Chichester, John Wiley and Sons, 2002:333-344.
23. Strom BL (ed.) Pharmacoepidemiology, 3rd ed. New York, NY, John Wiley and Sons, Ltd, 2002.
24. Mackay FJ. Post-marketing studies. The work of the Drug Safety Research Unit. Drug Safety, 1998, 19:343-353.
25. Bavdekar SB, Karande S. National pharmacovigilance program. Indian Pediatr. 2006 Jan;43(1):27-32. PMID: 16465003.
26. Khopkar U. Reporting of drug eruptions: the National Pharmacovigilance Program. Indian J Dermatol Venereol Leprol. 2005 Jan-Feb;71(1):1-2. doi: 10.4103/0378-6323.13776. PMID: 16394351.
27. Khan SA, Goyal C, Tonpay SD. A study of knowledge, attitudes, and practice of dental doctors about adverse drug reaction reporting in a teaching hospital in India. Perspect Clin Res. 2015 Jul-Sep;6(3):144-9. doi: 10.4103/2229-3485.159938. PMID: 26229750; PMCID: PMC4504056.
28. Domingues CM, Teixeira AM, Carvalho SM. National immunization program: vaccination, compliance and pharmacovigilance. Rev Inst Med Trop Sao Paulo. 2012 Oct;54 Suppl 18:S22-7. doi: 10.1590/s0036-46652012000700009. PMID: 23011456.
29. Singh P, Vaishnav Y, Verma S. Development of Pharmacovigilance System in India and Paradigm of Pharmacovigilance Research: An Overview. Curr Drug Saf. 2023;18(4):448-464. doi: 10.2174/1574886317666220930145603. PMID: 36200243.
30. Kalaiselvan V, Thota P, Singh GN. Pharmacovigilance Programme of India: Recent developments and future perspectives. Indian J Pharmacol. 2016 Nov-Dec;48(6):624-628. doi: 10.4103/0253-7613.194855. PMID: 28066097; PMCID: PMC5155460.
31. Prakash J, Sachdeva R, Shrivastava TP, Jayachandran CV, Sahu A. Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India. Indian J Pharmacol. 2021 Mar-Apr;53(2):143-152. doi: 10.4103/ijp.ijp_901_20. PMID: 34100398; PMCID: PMC8265409.
32. Thota P, Thota A, Medhi B, Sidhu S, Kumar P, Selvan VK, Singh GN. Drug safety alerts of pharmacovigilance programme of India: A scope for targeted spontaneous reporting in India. Perspect Clin Res. 2018 Jan-Mar;9(1):51-55. doi: 10.4103/picr.PICR_29_17. PMID: 29430420; PMCID: PMC5799955.
33. P. Biswas, A. K. Biswas Setting standards for proactive pharmacovigilance in India: The way forward. Indian J Pharmacol, 2007.39:124-128.
34. Jeetu G, Anusha G. Pharmacovigilance: a worldwide master key for drug safety monitoring. J Young Pharm 2010;2:315-20.
35. WHO. Safety monitoring of medicines. Guidelines for setting up and running a pharmacovigilance centre. Geneva, World Health Organization, 2000.
36. Livio F, Renard D, Buclin T. Pharmacovigilance. Rev Med Suisse 2012;8:116-9.
37. Lihite RJ, Lahkar M. An update on the Pharmacovigilance Programme of India. Front Pharmacol. 2015 Sep 22;6:194. doi: 10.3389/fphar.2015.00194. PMID: 26441651; PMCID: PMC4585088.
38. Bisht A, Singh S, Marwaha N. Hemovigilance program-India. Asian J Transfus Sci. 2013 Jan;7(1):73-4. doi: 10.4103/0973-6247.106744. PMID: 23559771; PMCID: PMC3613669.
39. Mishra HP, Gupta R. Leveraging Generative AI for Drug Safety and Pharmacovigilance. Curr Rev Clin Exp Pharmacol. 2024 Sep 5.
40. Ryan DK, Maclean RH, Balston A, Scourfield A, Shah AD, Ross J. Artificial intelligence and machine learning for clinical pharmacology. Br J Clin Pharmacol. 2024 Mar;90(3):629-639. doi: 10.1111/bcp.15930. Epub 2023 Nov 12. PMID: 37845024.
41. Roche V, Robert JP, Salam H. A holistic AI-based approach for pharmacovigilance optimization from patients behavior on social media. Artif Intell Med. 2023 Oct;144:102638. doi: 10.1016/j.artmed.2023.102638. Epub 2023 Aug 21. PMID: 37783543.
42. Dalsey T, Kim E, Chazin H, Ibrahim S. Global Postmarket Pharmacovigilance: A Generic Drug Perspective. Ther Innov Regul Sci. 2023 Nov;57(6):1180-1189. doi: 10.1007/s43441-023-00558-6. Epub 2023 Aug 10. PMID: 37563483.
43. Hegde M, Raj S, Tikadar D, Nyamagoud SB. Unveiling vaccine safety: a narrative review of pharmacovigilance in India's COVID-19 vaccination. Monaldi Arch Chest Dis. 2023 Dec 1. doi: 10.4081/monaldi.2023.2793. Epub ahead of print. PMID: 38037892.
44. Harpaz, R., et al. (2013). Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clinical Pharmacology & Therapeutics, 93(6), 539-546.
45. Almenoff, J. S., et al. (2007). Signal detection and evaluation in pharmacovigilance: a review. Drug Safety, 30(7), 609-621.
46. Coloma, P. M., et al. (2011). Electronic healthcare databases for active drug safety surveillance: is there enough leverage? Pharmacoepidemiology and Drug Safety, 20(6), 611-621.
47. Ball, R., & Dal Pan, G. (2018). Artificial intelligence for pharmacovigilance: what are the challenges? Drug Safety, 41(1), 1-3.
48. Kakalou C, Dimitsaki S, Dimitriadis VK, Natsiavas P. Exploiting Social Media for Active Pharmacovigilance: The PVClinical Social Media Workspace. Stud Health Technol Inform. 2022 Jun 6;290:739-743.
49. Potts J, Genov G, Segec A, Raine J, Straus S, Arlett P. Improving the Safety of Medicines in the European Union: From Signals to Action. Clin Pharmacol Ther. 2020 Mar;107(3):521-529.
50. Jiang Y, Xia JP, Yang JH, Zhang ZF, Hu CQ, Zhang ZR. Guidelines and strategy of the International Conference of Harmonization (ICH) and its member states to overcome existing impurity control problems for antibiotics in China. Chin J Nat Med. 2015 Jul;13(7):498-506.
51. Singh, H., & Rao, P. "A Comparative Analysis of Pharmacovigilance Systems: Developing Countries Versus Developed Countries." Pharmacoepidemiology and Drug Safety, vol. 29, no. 7, 2021, pp. 745–753.
52. Kapoor, P., & Kaur, M. "Artificial Intelligence in Pharmacovigilance: Current Trends and Future Directions." Journal of Drug Safety and Regulation, vol. 7, no. 4, 2023, pp. 199-207.
53. Singh, J., & Mishra, S. "Blockchain Technology and Its Role in Drug Safety Monitoring." International Journal of Emerging Technologies in Pharmaceutical Sciences, vol. 14, no. 2, 2022, pp. 88-93.
54. Li D, Wang H, Qin C, Du D, Wang Y, Du Q, Liu S. Drug-Induced Acute Pancreatitis: A Real-World Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database. Clin Pharmacol Ther. 2024 Mar;115(3):535-544. doi: 10.1002/cpt.3139. Epub 2024 Jan 2. PMID: 38069538.
55. Lasys T, Santa-Ana-Tellez Y, Siiskonen SJ, Groenwold RHH, Gardarsdottir H. Unintended impact of pharmacovigilance regulatory interventions: A systematic review. Br J Clin Pharmacol. 2023 Dec;89(12):3491-3502. doi: 10.1111/bcp.15874. Epub 2023 Aug 28. PMID: 37553757.
56. Harmark L, van Grootheest AC. Pharmacovigilance: Methods, recent developments and future perspectives. Eur J Clin Pharmacol 2008;64:743-52.